Putin says Moscow will never accept West’s position on death of Russian medics in SyriaRussian Politics & Diplomacy December 08, 18:44
Court postpones trial of FAS fine against Google until January 18Business & Economy December 08, 18:42
Putin: Russia won’t allow influence from outside through non-profit organizationsRussian Politics & Diplomacy December 08, 18:35
Dutch football club Vitesse denies media reports on Slutsky’s move from CSKA FCSport December 08, 18:03
Putin says it is necessary to combat extremism in social mediaRussian Politics & Diplomacy December 08, 17:36
Putin: Russia must remain secular state in relations with all religionsRussian Politics & Diplomacy December 08, 17:29
Russian Defense Ministry ready to assist in speedy delivery of aid to AleppoMilitary & Defense December 08, 17:22
Lavrov: Russia calls to set up anti-drug unit in OSCERussian Politics & Diplomacy December 08, 17:18
Top diplomat calls on NATO countries to stop military build-up near Russia’s bordersRussian Politics & Diplomacy December 08, 17:17
EINDHOVEN, Netherlands, Sept. 8, 2015 /PRNewswire/. As the number of trained pathologists decreases while the aging population and complexity of cancer is on the rise, Royal Philips (NYSE: PHG, AEX: PHIA) today announced the growing adoption of its Digital Pathology Solutions by health systems across the globe who are enhancing their operations. Through its IntelliSite Pathology Solution*, Philips enables health care organizations to reinvent the traditional histopathology workflow, enhance efficiency and productivity, and improve the confidence in making diagnosis.
Photo - http://photos.prnewswire.com/prnh/20150908/264234
Photo - http://photos.prnewswire.com/prnh/20150908/264235
Through examination of patient tissue samples, pathology plays a crucial role in the diagnosis, management and prevention of a variety of diseases, including cancer. As health care cost and quality pressures continue to mount, digital pathology can help improve the efficiency and quality of cancer diagnostics. Several high-volume and networked pathology institutions across the world have implemented the Philips digital pathology platform, which offers an integrated approach to improve workflows, enhance collaboration capabilities to speed up consults, unify patient data and enable a flexible growth path to get more information from tumor tissue.
"Modern pathology labs are coming under continued pressure to increase throughput and efficiency while improving quality," said Russell Granzow, General Manager of Philips Digital Pathology Solutions. "As the shift towards personalized medicine requires pathology data that guides the right therapy for the right patient at the right time, Philips is driving the evolution toward digitized workflows to ensure pathologists are empowered to meet industry demand."
Across the globe, leading institutions are leveraging Philips' experience in clinical digital transformation to help pathology laboratories make that next step in workflow improvement and accelerate knowledge sharing between care providers.
For further information, please contact:
Philips Digital Pathology Solutions
+31 6 10 610 417
Philips Group Communications
+31 6 1088 8824
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.
* Philips IntelliSite Pathology Solution is CE marked for primary diagnostics in the EU and Health Canada. In the U.S., Philips IntelliSite Pathology Solution is cleared by FDA for diagnostic use in the evaluation of HER2 expression in breast cancer and is offered for research use (RUO).